We rank companies based on fund manager, research analyst and news sentiment
GNTA

Genenta Science S.p.A. American Depositary Shares
GNTA

$3.4
1.91%
 

About: Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.

Employees: 14

0
Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

33% more funds holding

Funds holding: 3 [Q3] → 4 (+1) [Q4]

0.01% more ownership

Funds ownership: 2.51% [Q3] → 2.53% (+0.01%) [Q4]

9% less capital invested

Capital invested by funds: $2.29M [Q3] → $2.08M (-$210K) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for GNTA.

Financial journalist opinion